Didanosine - buffered and enteric-coated source regimens

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Historical source

Original GlobalRPh source

Product / population: Preserved GlobalRPh source, not a freshly verified product label
Renal measure: Use the method specified in the original source

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

The source uses >60 and <60 kg without defining exactly 60 kg; formulation-specific schedules have not been merged.

Usual Dosing (Adults)

To ensure adequate buffering, at least two tablets of the appropriate strength must be taken at each dose, whether once or twice daily.

Weight <60 kg: tablets 125 mg twice daily or 250 mg once daily; buffered powder 167 mg twice daily. Weight >60 kg: tablets 200 mg twice daily or 400 mg once daily; buffered powder 250 mg twice daily.

Renal Dosing

CrCl >60 mL/min: no change. Source schedules below distinguish tablets, buffered powder and Videx EC.

CrCl (mL/min)	Weight	Tablets	Buffered powder	Videx EC
30 to 59	>60 kg	100 mg twice daily or 200 mg daily	100 mg twice daily	200 mg daily
30 to 59	<60 kg	75 mg twice daily or 150 mg daily	100 mg twice daily	125 mg daily
10 to 29	>60 kg	150 mg daily	167 mg daily	125 mg daily
10 to 29	<60 kg	100 mg daily	100 mg daily	125 mg daily
<10	>60 kg	100 mg daily	100 mg daily	125 mg daily
<10	<60 kg	75 mg daily	100 mg daily	NR in source

The source's preceding table repeats these tablet and powder schedules.

Hemodialysis

Give 25% of usual dose daily. Supplemental doses are not necessary.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/didanosine/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Preserved GlobalRPh source

Original GlobalRPh protocol and comments

Preserved source. Not revalidated as current labeling.

Method: Use the measure stated in the original section.

Usual Dosing (Adults)Renal Dosing Hemodialysis Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope

Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The source uses >60 and <60 kg without defining exactly 60 kg; formulation-specific schedules have not been merged.

Compare original content

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/didanosine/

Usual Dosing (Adults)

To ensure adequate buffering, at least two tablets of the appropriate strength must be taken at each dose, whether once or twice daily.

Weight <60 kg: tablets 125 mg twice daily or 250 mg once daily; buffered powder 167 mg twice daily. Weight >60 kg: tablets 200 mg twice daily or 400 mg once daily; buffered powder 250 mg twice daily.

GRPH-didanosine-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl >60 mL/min: no change. Source schedules below distinguish tablets, buffered powder and Videx EC.

CrCl (mL/min)	Weight	Tablets	Buffered powder	Videx EC
30 to 59	>60 kg	100 mg twice daily or 200 mg daily	100 mg twice daily	200 mg daily
30 to 59	<60 kg	75 mg twice daily or 150 mg daily	100 mg twice daily	125 mg daily
10 to 29	>60 kg	150 mg daily	167 mg daily	125 mg daily
10 to 29	<60 kg	100 mg daily	100 mg daily	125 mg daily
<10	>60 kg	100 mg daily	100 mg daily	125 mg daily
<10	<60 kg	75 mg daily	100 mg daily	NR in source

The source's preceding table repeats these tablet and powder schedules.

GRPH-didanosine-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Give 25% of usual dose daily. Supplemental doses are not necessary.

GRPH-didanosine-03 · Source section: HemodialysisRenal section finder

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/renal/didanosine/
Source retrieval: 2026-09-05. This is not the source publication or label revision date.
Original source type: globalrph individual
Local text SHA-256: ad33803a77eccc20cf0f1384f933039167803a09dd8565e13c266e394219ed3b
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report